ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,035.69
      -1.57%
      US Tech 100
      16,983.60
      0.00%
      Dow Jones
      37,815.92
      0.00%
      Brent Oil
      85.175
      -0.84%
      Bitcoin
      58,002.70
      -4.29%
      Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Context Therapeutics Inc (CNTX)

      7. Context Therapeutics Inc (CNTX) News

      CNTX

      Context Therapeutics (CNTX)

      Context Therapeutics Inc
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:CNTX
      DateTimeSourceHeadlineSymbolCompany
      12:53PMiHub NewswireFeaturedCannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia
      04/01/20247:30AMGlobeNewswire Inc.Context Therapeutics Submits IND Application to Evaluate CTIM-76 in Claudin 6-Positive CancersNASDAQ:CNTXContext Therapeutics Inc
      03/21/20247:43AMGlobeNewswire Inc.Context Therapeutics Reports Full Year 2023 Operating and Financial ResultsNASDAQ:CNTXContext Therapeutics Inc
      03/06/20247:30AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:CNTXContext Therapeutics Inc
      02/07/20244:24PMEdgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:CNTXContext Therapeutics Inc
      11/09/20234:15PMGlobeNewswire Inc.Context Therapeutics Reports Third Quarter 2023 Operating and Financial ResultsNASDAQ:CNTXContext Therapeutics Inc
      11/09/20234:04PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CNTXContext Therapeutics Inc
      10/31/20239:04AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:CNTXContext Therapeutics Inc
      10/31/20239:00AMGlobeNewswire Inc.Context Therapeutics Announces Preclinical Data Demonstrating Differentiated and Active Profile of its Claudin 6-Targeted Bispecific Antibody CTIM-76NASDAQ:CNTXContext Therapeutics Inc
      09/27/20239:00AMGlobeNewswire Inc.Context Therapeutics Announces Acceptance of Abstract to be Presented at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual MeetingNASDAQ:CNTXContext Therapeutics Inc
      08/09/20234:10PMGlobeNewswire Inc.Context Therapeutics Reports Second Quarter 2023 Operating and Financial ResultsNASDAQ:CNTXContext Therapeutics Inc
      08/09/20234:04PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CNTXContext Therapeutics Inc
      08/07/20238:11AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:CNTXContext Therapeutics Inc
      08/01/20237:30AMGlobeNewswire Inc.Context Therapeutics to Participate in Two August 2023 Investor ConferencesNASDAQ:CNTXContext Therapeutics Inc
      06/20/20238:36AMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:CNTXContext Therapeutics Inc
      05/31/20234:53PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:CNTXContext Therapeutics Inc
      05/10/20234:39PMGlobeNewswire Inc.Context Therapeutics Reports First Quarter 2023 Operating and Financial ResultsNASDAQ:CNTXContext Therapeutics Inc
      04/03/20237:30AMGlobeNewswire Inc.Context Therapeutics to Participate in Two April 2023 Investor ConferencesNASDAQ:CNTXContext Therapeutics Inc
      03/27/20234:04PMEdgar (US Regulatory)Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a)NASDAQ:CNTXContext Therapeutics Inc
      03/22/20235:10PMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:CNTXContext Therapeutics Inc
      03/22/20235:08PMGlobeNewswire Inc.Context Therapeutics Reports Full Year 2022 Financial Results and Recent Pipeline UpdatesNASDAQ:CNTXContext Therapeutics Inc
      03/15/20237:30AMGlobeNewswire Inc.Context Therapeutics Announces Acceptance of Abstract to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2023NASDAQ:CNTXContext Therapeutics Inc
      02/14/20235:26PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:CNTXContext Therapeutics Inc
      02/14/20235:26PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:CNTXContext Therapeutics Inc
      02/14/20235:25PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:CNTXContext Therapeutics Inc
      02/14/20234:05PMEdgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:CNTXContext Therapeutics Inc
      02/13/20234:04PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:CNTXContext Therapeutics Inc
      02/06/20234:04PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:CNTXContext Therapeutics Inc
      02/06/20237:30AMGlobeNewswire Inc.Context Therapeutics Highlights Clinical Responses from the Phase 2 OATH Clinical Trial Evaluating ONA-XR for the Treatment of Endometrial CancerNASDAQ:CNTXContext Therapeutics Inc
      01/31/20237:30AMGlobeNewswire Inc.Context Therapeutics’ Clinical Partner Stemline Therapeutics, a Subsidiary of Menarini Group Receives FDA Approval of ORSERDU™ (elacestrant) in ER+, HER2-, ESR1-mutated Breast CancerNASDAQ:CNTXContext Therapeutics Inc
       Showing the most relevant articles for your search:NASDAQ:CNTX